

## Mendelian randomisation identifies priority groups for prophylactic EBV vaccination

Muckian, Marisa D.; Wilson, James F.; Taylor, Graham S.; Stagg, Helen R.; Pirastu, Nicola

DOI:

[10.1186/s12879-023-08031-3](https://doi.org/10.1186/s12879-023-08031-3)

License:

Creative Commons: Attribution (CC BY)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Muckian, MD, Wilson, JF, Taylor, GS, Stagg, HR & Pirastu, N 2023, 'Mendelian randomisation identifies priority groups for prophylactic EBV vaccination', *BMC Infectious Diseases*, vol. 23, no. 1, 65.  
<https://doi.org/10.1186/s12879-023-08031-3>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.


If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

RESEARCH ARTICLE

Open Access



# Mendelian randomisation identifies priority groups for prophylactic EBV vaccination

Marisa D. Muckian<sup>1\*</sup> , James F. Wilson<sup>1,2</sup>, Graham S. Taylor<sup>3</sup>, Helen R. Stagg<sup>1†</sup> and Nicola Pirastu<sup>1,4†</sup>

## Abstract

**Background** Epstein Barr virus (EBV) infects ~95% of the population worldwide and is known to cause adverse health outcomes such as Hodgkin's, non-Hodgkin's lymphomas, and multiple sclerosis. There is substantial interest and investment in developing infection-preventing vaccines for EBV. To effectively deploy such vaccines, it is vital that we understand the risk factors for infection. Why particular individuals do not become infected is currently unknown. The current literature, describes complex, often conflicting webs of intersecting factors—sociodemographic, clinical, genetic, environmental-, rendering causality difficult to decipher. We aimed to use Mendelian randomization (MR) to overcome the issues posed by confounding and reverse causality to determine the causal risk factors for the acquisition of EBV.

**Methods** We mapped the complex evidence from the literature prior to this study factors associated with EBV serostatus (as a proxy for infection) into a causal diagram to determine putative risk factors for our study. Using data from the UK Biobank of 8422 individuals genomically deemed to be of white British ancestry between the ages of 40 and 69 at recruitment between the years 2006 and 2010, we performed a genome wide association study (GWAS) of EBV serostatus, followed by a Two Sample MR to determine which putative risk factors were causal.

**Results** Our GWAS identified two novel loci associated with EBV serostatus. In MR analyses, we confirmed shorter time in education, an increase in number of sexual partners, and a lower age of smoking commencement, to be causal risk factors for EBV serostatus.

**Conclusions** Given the current interest and likelihood of a future EBV vaccine, these factors can inform vaccine development and deployment strategies by completing the puzzle of causality. Knowing these risk factors allows identification of those most likely to acquire EBV, giving insight into what age to vaccinate and who to prioritise when a vaccine is introduced.

**Keywords** Mendelian randomization, Epstein–Barr virus, Epidemiology, Public health, Vaccination

<sup>†</sup>Helen R. Stagg and Nicola Pirastu these two authors contributed equally.

\*Correspondence:

Marisa D. Muckian  
m.muckian@sms.ed.ac.uk

<sup>1</sup> Old Medical School, Usher Institute, University of Edinburgh, Teviot Place, Edinburgh EH8 9AG, UK

<sup>2</sup> MRC Human Genetics Unit, Institute of Genetics and Cancer, Western General Hospital, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK

<sup>3</sup> Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham B15 2TT, UK

<sup>4</sup> Human Technopole, Viale Rita Levi-Montalcini, 1, Area MIND–Cargo 6, 20157 Milan, Italy



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Background

Epstein Barr Virus (EBV) is a human herpes virus infecting 95% of the global population. It is associated with multiple cancers including Hodgkin's and non-Hodgkin's lymphomas, nasopharyngeal carcinoma and gastric adenocarcinoma, resulting in nearly 164,000 cancer deaths per year. Furthermore, EBV has been associated with the neurological condition multiple sclerosis which affects 2.8 million people globally, particularly in North America, western Europe and Australasia [1, 2]. The burden of disease associated with EBV is such that interest in the development of infection- or disease-preventing vaccines is extensive. In recent years a Phase II trial of an early vaccine candidate to prevent infectious mononucleosis (IM) only reduced symptom severity upon infection [3]. Subsequently, substantial investment has been placed in developing more immunogenic candidates [4]. Efforts have been given a boost by the successful mRNA vaccines developed by Pfizer/BioNTech and Moderna against SARS-CoV-2. Indeed, Moderna currently have a mRNA-based EBV vaccine candidate in clinical development [5].

Our knowledge on the risk factors for the acquisition of EBV is poor, and yet this is critical for two reasons. Firstly, to determine how best to deploy an infection-preventing vaccine. For example, determining the age at which vaccination should take place based on age of exposure to the determined risk factors. Secondly, it is also important that we understand why some individuals remain EBV negative for life and the consequences of this status, given that such vaccines will 'induce' a state of potentially lifelong non-infection in millions of people.

Extensive work has been undertaken internationally to determine the risk factors for EBV infection, but these studies have been hindered by the limitations of traditional epidemiology. In a recent systematic review [6], we mapped the highly complex webs of—often contradictory—evidence available to date, and the extent that it is likely to be impacted by unmeasured confounding and reverse causality. Studies to date have largely focused on sociodemographic, dietary, and lifestyle factors, although some of these risk factors are consistently displayed from setting to setting (age being the clearest example). Additionally, a small number of studies have examined genetic susceptibility to EBV infection (the presence or absence of) [7–13]. More recent studies have identified genetic variants associated specifically with levels of antibodies against EBV [9, 10, 14]. One of the issues with improving the evidence is the cost associated with running large, data-rich, cohort studies for which information on all potential risk factors and confounding factors is captured.

Mendelian randomisation (MR) is a technique that takes advantage of genetic data to understand if a putative risk factor of interest is causally associated with a given health outcome [15]. Unlike traditional epidemiological studies, MR eliminates the issues of unmeasured confounding and reverse causality using instrumental variables (IVs), which are genetic variants known to be associated with the risk factor. This means it is possible to accurately determine if a putative risk factor is causally associated with an outcome, provided the assumptions of MR are met and relevant genetic data are available.

This study sought to unravel the Gordian knot of risk factors for the acquisition of EBV, in preparation for the deployment of prophylactic vaccination candidates. We performed a genome-wide associated study (GWAS) to determine the genetic risk factors for EBV infection, followed by an MR to interrogate the published putative non-genetic factors, all within the UK Biobank (UKB; a UK based cohort study of people aged between 40 and 69 years) [16]. Our study demonstrates the power of MR in overcoming the pitfalls of traditional epidemiological approaches, not only for EBV, but also for other complex infectious diseases.

## Methods

In order to perform an MR on the association between the acquisition of EBV infection and different putative risk factors, we undertook the following steps, each of which are laid out in separate sections of the methods. (1) Identify a population of interest for the analysis within which (2) EBV serostatus (as a proxy for infection) had been tested for and (3) which had been genotyped. (4) Identify the putative risk factors of interest for EBV infection from the published literature. (5) Descriptively analyse the population of interest in light of the putative risk factors of interest. (6) Find corresponding existing GWASs to extract instrumental variables (genetic variants known to be associated our putative risk factors of interest. (7) Undertake a GWAS of EBV serostatus and where pre-existing GWASs could not be found for a putative risk factor of interest. (8) Perform MR.

### Study population

UKB is a prospective cohort study of over 500,000 participants recruited in the UK between 2006 and 2010. Participants of the UKB were aged between 40 and 69 years old at the time of recruitment [16].

### Epstein–Barr virus serostatus

A randomly selected subset of 9695 participants in the UKB were subject to serological testing on samples taken at the point of their enrolment into the cohort, including

for anti-EBV antibodies [17]. A multiplex serology-based approach, as described by Brenner et al. [18], was used for testing. Antibody levels against different EBV antigen targets were expressed as median fluorescence intensity (MFI). (Data were recorded by the UKB as both antibody levels against each antigen and in a binary format (seropositive/seronegative) for overall EBV serostatus if two or more MFI thresholds were met. As EBV is a herpesvirus that establishes a lifelong infection in humans, we used serostatus as a proxy for EBV infection throughout our analyses.

### Genotyping

Participants of the UKB had DNA extracted from samples taken during their initial visit to one of 22 assessment centres. Genotyping was carried out using the Applied Biosystems UK Biobank Axiom Array and the UK BiLEVE array. Autosomal single nucleotide polymorphisms (SNPs) were imputed using a merged reference panel of the Phase 3 1000 Genome Project and UK10K using IMPUTE3. Procedures are described in full by Bycroft et al. [16].


### Exposures to be tested for causal effect on EBV serostatus

Non-genetic variables to be tested for a putatively causal effect on EBV serostatus through MR were selected based on a review by Winter et al. [6]. Six factors (childhood household size, total number of sexual partners,

BMI, tonsillectomy, educational attainment, smoking status) were selected on the basis of the balance of evidence within the review being in favour of a putative causal effect (Additional file 1: Table S1) and mapped into a causal diagram (Fig. 1) in broad groups: household size, lifestyle factors (smoking status), socioeconomic factors (educational attainment), genetic factors, clinical factors (BMI, tonsillectomy). The review found coinfection with other several other viruses to be associated with EBV status including: human immunodeficiency virus (HIV), Kaposi's sarcoma related herpes virus (KSHV), human T-lymphotropic virus (HTLV), CMV, and herpes-simplex 1 (HSV-1). We did not include these in our MR studies due to potential of overlapping genetic variants that may influence both the risk factor infection and EBV.

### Descriptive analysis

A descriptive analysis of the demographics of the overall UKB cohort and the subcohort of individuals with EBV serostatus and who were genomically deemed to be of white British ancestry (see genome-wide association study section of the methods) was carried out using R (v3.6.1) [19]. Qualitative traits are reported as a % total (N). Normality of the quantitative variables was assessed using a Kolmogorov–Smirnov test and non-normally distributed traits were subsequently expressed using the median and interquartile range.



**Fig. 1** Causal diagram of risk factors for EBV infection. Diagram contains risk factors mapped to broad categories such as household size, lifestyle factors (smoking status), socioeconomic factors (educational attainment), and clinical factors (body mass index, tonsillectomy)

### Exposure instrumental variable selection

Next, IVs for each exposure (genetic variants associated with the exposures i.e., putative risk factors, in this case, SNPs) were selected. From the causal diagram, six putative risk factors were selected. For all risk factors apart from household size, IVs were obtained from previously published GWAS results (Additional file 1: Table S2). For each exposure variable, the largest and most recent GWAS performed in European samples was used. From each exposure GWAS we selected genome wide significant ( $p < 5 \times 10^{-8}$ ) and independent SNPs ( $r^2 < 0.0001$ ) using the TwoSampleMR package. For total number of siblings GWAS results were not available, thus we performed our own GWAS using the individuals from UKB who did not participate in the serological study ( $N = 319,209$ ). For total number of siblings, we combined the total number of sisters and total number of brothers variables as reported in the questionnaire of UKB. GWAS methods are described below.

### Genome-wide association study for EBV serostatus


As a preparatory step for the MR, we carried out two GWAS: (1) of EBV serostatus on the subcohort, our MR outcome variable and (2) of household size as measured by total number of siblings, as no IV could be identified from the literature for this putative risk factor. These were carried out on UKB participants with genomic data, including only unrelated individuals and those who were genomically deemed to be of white British ancestry determined using a principal component analysis (PCA) performed by UKB [16]. Genome-wide association was performed using a two-step regression framework, which first created phenotype residuals adjusted for technical genotyping covariates and population structure, before regressing these residuals against SNP dosage. This two-step approximation (GRAMMAR-Gamma) is commonly used in large GWAS of related individuals to reduce the computational burden by fitting a mixed model only once for each phenotype, instead of fitting the model for every SNP [21]. Using a purpose-built GWAS pipeline, two phenotypes were regressed against the fixed effect covariates (sex, age, genotyping batch, array type, and the first 40 principal components (PCs) as calculated by UKB to account for population substructure) [20]. Fixed effect residuals were then further regressed against a random effect covariate of relatedness, based on the variance of the sparse genetic relatedness matrix using FastGWA [21]. Finally, the FastGWA residuals were regressed against genome-wide SNP dosages using RegScan [22]. Genome-wide association was performed using a linear regression model. Genome-wide significant loci were defined using a p-value threshold of  $5 \times 10^{-8}$ . The resulting SNPs from the total number of siblings GWAS were

chosen as IVs for MR analysis and included independent significant SNPs ( $r^2 = 0.001$ ,  $p\text{-value} = 5 \times 10^{-8}$ ).

### Mendelian randomization

MR analysis allows us to determine the causal role that a given exposure (X) has on a given outcome (Y) without the impact of confounding. Genetic instruments—such as SNPs—that directly affect the exposure of interest, can be used as IVs to determine the exposure's effect on a specific outcome. If individuals with genetic variants associated with the risk factor, have a higher incidence of the outcome, in this case EBV seropositivity, we can conclude that the risk factor is causal for EBV. Genetic variants are valid instruments so long as they are not also associated with the outcome and are not influenced by any confounders (U) (Fig. 2).

For this study we used Two-Sample MR, in which the effects of the SNP on the exposure and the outcome are estimated in two distinct set of samples. The two effect sizes are harmonized, to ensure both the outcome and exposure effects align to the same allele. The effect of the exposure on the outcome is then estimated. This method was used to test if seven (including two measures of smoking status, age at smoking initiation and ever smoking) previously identified putative risk factors had a role in influencing risk of EBV infection. As an outcome, we used our EBV serostatus GWAS. The exposure and outcome data were harmonised before MR was performed. We firstly detected outliers using the RadialMR package and IVW radial function. We then removed these outliers from the harmonised data. To test the validity of our causal inferences we carried out multiple sensitivity analyses. Firstly, using TwoSampleMR, we calculated Cochran's Q statistic to assess heterogeneity of the genetic instruments. We then checked for directional pleiotropy using the Egger regression function. To ensure no single genetic variant was impacting the causal estimate of our results, we performed a leave one out analysis using TwoSampleMR.



**Fig. 2** Mendelian randomization. Mendelian randomization uses genetic instruments ( $G_j$ ) associated with the exposure (X) of interest as instrumental variables, to determine the causal relationship of X on the outcome (Y) without the influence of confounding. The instruments must not be associated with any confounders (U)



Multivariable MR (MVMR) was planned to assess for correlation of significant factors at the univariable stage using the Mendelian randomization package [23].

## Results

### Descriptive analysis

Of the 9695 individuals within the UKB sub-cohort that underwent serological testing, 8244 (97.3%) had available results for EBV serostatus and were genomically deemed to be of white British ancestry (Additional file 1: Table S3, which also compares the subcohort the overall UKB cohort). Of those 7795 (94.6%) were EBV seropositive. The age and sex distribution within the sub-cohort were similar to that of the main cohort.

### Genome-wide association study

GWAS of EBV serostatus (positive or negative) revealed two independent genome-wide significant loci for EBV serostatus ( $p \leq 5 \times 10^{-8}$ ) (Additional file 1: Fig. S1, Table S4). The first locus was located on chromosome 13 and mapped nearest to *RASA3*, (rs71449058,  $p = 2.34 \times 10^{-10}$ ); effect allele C has a protective effect against EBV. The second locus was on chromosome 6 and the nearest gene *PREP* (rs1210063,  $p = 4.01 \times 10^{-9}$ ), the effect allele G was found to increase susceptibility to EBV.

### Mendelian randomization

Taking the results of our GWAS, we next sought to determine if our putative risk factors for EBV serostatus were, in fact, causal. After removal of outlying IVs (Additional file 1: Table S5), univariable MR showed that educational attainment ( $p = 7.20 \times 10^{-6}$ ), sexual partners ( $p = 0.02$ ), and smoking ( $p = 0.049$ ) were found to be associated with EBV serostatus (Table 1). For each additional year of genetically predicted education (baseline 0 years) the odds of being EBV seropositive decreased (OR = 0.43, 95% CI = 0.30–0.62). Compared to previous studies this we observed the opposite direction of effect (Fig. 3) although effect size was difficult to compare due to differences in exposure measurements. As the total number of sexual partners increased from < 2 partners to between 2 and 5, the odds of being EBV seropositive increased to 2.69 (95% CI = 1.15–6.32), consistent with previous literature. Finally, being a smoker (previous or current) increased the odds of EBV 2.36 times (95% CI = 1.00–5.55). No other putative risk factors were found to be associated with EBV serostatus.


Sensitivity analyses demonstrated no significant heterogeneity between the estimate from each of the exposure IVs and EBV status while we detected no sign of directional pleiotropy when tested using Egger regression. Finally leave-one-out analysis showed the observed effect

**Table 1** Univariable Mendelian randomization of putative risk factors for EBV infection

Risk factor	N SNPS	OR (95% CI)	P-value
Total number of siblings	5		0.84
Per increase of 1		1.15 (0.30–4.38)	
Number of sexual partners <sup>a</sup>	61		0.02
< 2		Baseline	
2–5		2.69 (1.15–6.32)	
BMI	464		0.29
Per unit increase		1.14 (0.89–1.46)	
Tonsillectomy	10		0.37
No		Baseline	
Yes		0.01 ( $5.5 \times 10^{-7}$ –220.33)	
Educational attainment (years)	291		$7.20 \times 10^{-6}$
0		Baseline	
Per increase of 1		0.43 (0.30–0.62)	
Smoking status	10		0.049
Never		Baseline	
Ever		2.36 (1.00–5.55)	
Age at smoking initiation (years)	1		0.80
Per unit increase		0.92 (0.47–1.79)	

Putative risk factors include, total number of siblings, total number sexual partners (< 2, 2–5,  $\geq 5$ )<sup>a</sup> (OR only calculated for < 2 and 2–5), BMI, Tonsillectomy (yes/no), Educational attainment (years), smoking status (never/ever), age at smoking initiation (years). Risk factors with  $p \leq 0.05$  were considered significant

BMI body mass index, CI confidence intervals, N number, OR odds ratio, SNPs single nucleotide polymorphisms



**Fig. 3** Mendelian randomization results compared to previous observational studies for educational attainment, number of sexual partners and smoking status. Our educational attainment MR compared to an observational study in Taiwan (Baseline = uneducated) by Chen et al. [28]. The sexual partners MR compared to observational effects converted from risk factors from a previous study by Crawford et al. [29] (Baseline = 0). Smoking status MR compared to a study by Levine et al. [30] (Baseline = never smoked). *MR* Mendelian randomization

was constant and not driven by any single SNP (Additional file 1: Fig. S2a–c).

### Multivariable Mendelian randomization

To determine if education, total number of sexual partners and smoking were independent risk factors for EBV we performed MVMR (Table 2). Results indicated that educational attainment was an independent risk factor for EBV (OR = 0.46, 95% CI = 0.32–0.67,  $p = 3 \times 10^{-6}$ ). Smoking also was an independent risk factor (OR = 4.13,

95% CI = 1.51–11.30,  $p = 0.006$ ). The total number of sexual partners had a similar OR to the univariable analysis [OR = 2.12, 95% CI = (0.66–6.82)], but the result was not statistically significant ( $p = 0.206$ ). This could be due to fewer IVs in the MVMR being associated with total number of sexual partners, reducing power.

### Discussion

In this study, we present the first MR to examine the causality of potential risk factors for the acquisition EBV. Our MR analysis of previously identified risk

**Table 2** Multivariable Mendelian randomization of risk factors for EBV infection

Trait	OR (95% CI)	p-value
Educational attainment (years)		$3 \times 10^{-6}$
Per increase of 1	0.47 (0.33–0.67)	
Total number of sexual partners		0.21
< 2		
2–5	2.12 (0.66–6.82)	
Smoking status		0.006
Never	Baseline	
Ever	4.13 (1.51–11.30)	

Model adjusted for three risk factors, total number sexual partners (< 2, 2–5,  $\geq 5$ ), educational attainment (years), smoking status (yes/no), Risk factors with  $p \leq 0.05$  were considered significant

CI confidence intervals, OR odds ratio

factors and EBV serostatus demonstrates how MR can be used to unpick the available, at times conflicting, evidence on the complex spectrum of factors that pose a risk for the acquisition of an infectious disease. This is not only the case for EBV, but it also provides a proof of principle for other infectious diseases. In our study we identified two loci (rs1210063 and rs71449058) associated with EBV infection through an initial GWAS and provided evidence that the non-genetic factors educational attainment and number of sexual partners and smoking are likely causally associated with infection.

Examining the loci documented within our GWAS first, previous publications have documented that one of the nearest genes to these loci have previously been discussed in the EBV literature (*RASA3*). This gene locates near viral protein binding sites that may enhance regulation of the EBV lytic cycle [24].

Comparing our findings to previous studies of the genetics of EBV infection, it is interesting to note that such studies have focused primarily on antibody levels. Anti-EBNA-1 levels have been established to associate strongly with the HLA class II region [9–12, 14] and more recently this region was found to be associated with anti-VCA IgG [14]. In a recent publication, Butler-Laporte et al. found similar results to our GWAS, despite slight differences in sample selection, the top SNP for EBV seropositivity documented in that publication—rs71437272—showed a similarly strong result in our analysis [13].

While our GWAS results provided insight into the genetic susceptibility component of our causal framework, they also gave us the tools required to untangle the conflicted evidence reported in the literature for EBV risk factors. An increased number of sexual partners and either being or having been a smoker increased

risk of EBV. We found that having a higher educational attainment was protective for EBV in univariable MR, in contrast to the results of Chen et al. [25], possibly due to differential access to education at the relevant time points in the UK and Taiwan. Given the association in the UK between years spent in education and socioeconomic status, as well as smoking and socioeconomic status, these two findings correlate within our MR. MVMR found smoking and educational attainment to be independent risk factors for EBV status. The direction of the effect of these risk factors is consistent with the previous literature [25–28]. In contrast, BMI, age at smoking initiation, total number of siblings, and having your tonsils removed were not associated with EBV in this MR analysis.

With the recent surge in interest in EBV infection-preventing vaccines, our results present an intriguing insight into the future deployment of such products on the basis of known risk factors for EBV infection. For example, the cost of a future vaccine may limit publicly funded deployment to particularly at-risk groups from EBV associated diseases. There is a known association between EBV acquisition at later life stages, infectious mononucleosis and then cancer [29], as well as a likely strong association between the time point of acquisition and population level socioeconomic status [6]. Thus our documentation of two individual level socioeconomically associated factors (smoking [30] and years in education) as likely causally associated with infection demonstrates an opportunity for targeted deployment of the vaccine to particular population groups. Whilst it is not possible to deploy a vaccine on the basis of a factor such as smoking status, doing so on the basis of enrolment in different levels of education is commonly used for other infectious diseases e.g. meningitis A, C, W, Y.

The core strength of our study is the use of MR to unpicking the previously disagreed upon or at times opposing evidence of causality for the risk factors for an EBV without confounding or reverse causality. Although our study population was restricted to individuals genomically deemed to be of white British ancestry, limiting generalisability. Moreover, only three (3/77) studies used to identify putative EBV risk factors from the review by Winter et al., were from the UK population and two of the observational studies used in comparison to the MR results are from Taiwan (education) and Israel (smoking). EBV seroprevalence and the age by which seroprevalence reaches equilibrium varies between populations [6] and both genetic and non-genetic factors are likely to vary too. Additional studies across populations of different ancestries are required. Data were only available on EBV serostatus at baseline within the UKB, limiting our ability to examine risk factors in temporal proximity to EBV acquisition. UKB, like many population cohorts, is known



to not be truly representative of the general population and is particularly enriched for individuals of higher educational status. There is also evidence that EBV infectivity rates differ between EBV strains (type 1 and type 2), and so the viral genome might influence conversion rates [31]. However, no viral genetic data were available in our study. The previous observational studies used to test our hypothesis also did not distinguish between EBV type. Finally, our study had limited power due to 95% of individuals being EBV seropositive.

Despite these limitations, we found MR to be a powerful tool to clearly define a core set of risk factors for the acquisition of EBV. These factors are informative for future vaccine deployment and should be measured and then adjusted for in analyses of the acquisition of EBV. Other infectious diseases for which MR would be similarly useful include respiratory syncytial virus (RSV). A review of the putative risk factors for RSV and acute lower respiratory infections from 2015 described the huge variation between studies in how risk factors are measured, and which confounders are adjusted for [32]. The effect estimates in these studies were thought to be impacted substantially by confounding and the biased measurement of putative risk factors; MR has the potential to solve this issue by pinpointing which risk factors to measure and adjust for.

The effective deployment of anti-EBV vaccines will not be possible without a better grasp on the acquisition of infection than has been provided by epidemiological studies to date. Using MR, we demonstrate a low-cost and effective way of untangling the published literature and pinpoint critical factors to consider when vaccine candidates come onto the market.

## Conclusions

Given the likelihood that an EBV vaccine will become available, we have identified key sociodemographic risk factors that will aid identification of target groups for priority vaccination. We also ruled out several disputed factors identified in previous literature, implicating the usefulness of MR in the study of infectious disease risk factors.

## Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12879-023-08031-3>.

**Additional file 1: Table S1.** Putative non-genetic risk factors for Epstein Barr virus infection to be explored in the Mendelian randomisation. **Table S2.** Table of GWAS studies used in Mendelian randomization analysis. **Table S3.** Demographic and clinical baseline data for the UK Biobank cohort versus the sub-cohort for analysis. **Figure S1.** Manhattan plot of EBV serostatus loci. **Table S4.** Significant GWAS hits of EBV serostatus. **Table S5.** Table of heterogeneity statistics from TwoSampleMR package

and number of outliers detected. **Figure S2.** (a) Leave one out analysis for educational attainment. (b) Leave one out analysis for lifetime number of sexual partners. (c) Leave one out analysis for age at smoking initiation.

## Acknowledgements

The authors wish to acknowledge Dr. Athina Spiliopoulou for useful methodological discussions and guidance.

## Author contributions

MDM, HRS, NP, and GT conceived of the work. MDM, HRS and NP designed the work. MDM and NP analysed the data for the work. All authors interpreted the data for the work. MDM drafted the work. All authors revised it critically for important content. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors read and approved the final manuscript.

## Funding

MDM's Ph.D. is funded by the University of Edinburgh, UK. JFW acknowledges support from the MRC Human Genetics Unit programme grant, "Quantitative traits in health and disease" (U. MC\_UU\_00007/10). GT would like to acknowledge funding from Cancer Research UK award C8781/A13174. HRS is supported by the UK Medical Research Council (MRC) [MR/R008345/1]. NP has no funding to declare. Funding bodies had no responsibility for study design, data collection, analysis, interpretation of data or in writing of this manuscript.

## Data availability

The source data are available to researchers upon application to UK Biobank using the UKBiobank data access process (<http://www.ukbiobank.ac.uk/regist-apply/>). Full GWAS summary statistics for our EBV serostatus and total number of siblings can be found at <https://doi.org/10.7488/ds/3797>. Summary statistics for smoking status and age of smoking initiation can be downloaded from (<https://conservancy.umn.edu/handle/11299/201564>). Summary statistics for lifetime number of sexual partners (ukb-b-4256), tonsillectomy (ukb-b-15096), BMI (ieu-b-40) and educational attainment (ieu-a-1239) can be downloaded from the open GWAS project (<https://gwas.mrcieu.ac.uk/>).

## Declarations

### Ethics approval and consent to participate

This analysis of secondary data was sponsored by the Academic and Clinical Central Office for Research and Development (ACCORD) of the University of Edinburgh and National Health Service Lothian, UK (AC19175). The research conducted within this study was assessed using an Usher Institute, University of Edinburgh Level 1 Ethics Self-Audit, which demonstrated that it posed no reasonably foreseeable ethical risks and so was exempt from formal ethic review by the Usher Research Ethics Group. The UK Biobank genotypic and phenotypic data used in this study were approved under application 19655.

### Consent for publication

Not applicable.

### Competing interests

All authors declare no conflicts of interest.

Received: 1 August 2022 Accepted: 24 January 2023

Published online: 03 February 2023

## References

1. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein–Barr virus associated with multiple sclerosis. *Science*. 2022. <https://doi.org/10.1126/science.abj8222>.
2. Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. *Mult Scler J*. 2020;26:1816–21.

3. Sokal EM, Hoppenbrouwers K, Vandermeulen C, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein–Barr virus vaccine in healthy young adults. *J Infect Dis*. 2007;196:1749–53.
4. Kanekiyo M, Bu W, Joyce MG, et al. Rational design of an Epstein–Barr virus vaccine targeting the receptor-binding site. *Cell*. 2015;162:1090–100.
5. Sun C, Chen X, Kang Y, Zeng M. The status and prospects of Epstein–Barr virus prophylactic vaccine development. *Front Immunol*. 2021. <https://doi.org/10.3389/fimmu.2021.677027>.
6. Winter JR, Jackson C, Lewis JE, Taylor GS, Thomas OG, Stagg HR. Predictors of Epstein–Barr virus serostatus and implications for vaccine policy: a systematic review of the literature. *J Glob Health*. 2020. <https://doi.org/10.7189/jogh.10.010404>.
7. Durovic B, Gasser O, Gubser P, et al. Epstein–Barr virus negativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants and tonsillectomy. *J Virol*. 2013;87:6526–9.
8. Friberg JT, Jarrett RF, Koch A, et al. Mannose-binding lectin genotypes and susceptibility to Epstein–Barr virus infection in infancy. *Clin Vaccine Immunol*. 2010;17:1484–7.
9. Sallah N, Carstensen T, Wakeham K, et al. Whole-genome association study of antibody response to Epstein–Barr virus in an African population: a pilot. *Glob Health Epidemiol Genom*. 2017. <https://doi.org/10.1017/gheg.2017.16>.
10. Rubicz R, Yolken R, Drigalenko E, et al. A genome-wide integrative genomic study localizes genetic factors influencing antibodies against Epstein–Barr virus nuclear antigen 1 (EBNA-1). *PLoS Genet*. 2013. <https://doi.org/10.1371/journal.pgen.1003147>.
11. Hammer C, Begemann M, McLaren PJ, et al. Amino acid variation in HLA class II proteins is a major determinant of humoral response to common viruses. *Am J Hum Genet*. 2015;97:738–43.
12. Scepanovic P, Alanio C, Hammer C, et al. Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines. *Genome Med*. 2018;10:59.
13. Butler-Laporte G, Kreuzer D, Nakanishi T, Harroud A, Forgetta V, Richards JB. Genetic determinants of antibody-mediated immune responses to infectious diseases agents: a genome-wide and HLA association study. *Open Forum Infect Dis*. 2020;7: ofaa450.
14. Sallah N, Miley W, Labo N, et al. Distinct genetic architectures and environmental factors associate with host response to the  $\gamma$  2-herpesvirus infections. *Nat Commun*. 2020;11:3849.
15. Davies NM, Holmes MV, Smith GD. Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. *BMJ*. 2018;362: k601.
16. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*. 2018;562:203–10.
17. Mentzer AJ, Brenner N, Allen N, et al. Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank. *Infect Dis (Except HIV/AIDS)*. 2019. <https://doi.org/10.1101/19004960>.
18. Brenner N, Mentzer AJ, Butt J, et al. Validation of multiplex serology detecting human herpesviruses 1–5. *PLoS ONE*. 2018;13: e0209379.
19. R: a language and environment for statistical computing. 2019. <https://www.R-project.org>.
20. Bycroft C, Freeman C, Petkova D, et al. Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv*. 2017. <https://doi.org/10.1101/166298>.
21. Jiang L, Zheng Z, Qi T, et al. A resource-efficient tool for mixed model association analysis of large-scale data. *Nat Genet*. 2019;51:1749–55.
22. Haller T, Kals M, Esko T, Mägi R, Fischer K. RegScan: a GWAS tool for quick estimation of allele effects on continuous traits and their combinations. *Brief Bioinform*. 2015;16:39–44.
23. Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. *Int J Epidemiol*. 2017;46:1734–9.
24. Ramasubramanian S, Osborn K, Al-Mohammad R, et al. Epstein–Barr virus transcription factor Zta acts through distal regulatory elements to directly control cellular gene expression. *Nucleic Acids Res*. 2015;43:3563–77.
25. Chen C-Y, Huang K-YA, Shen J-H, Tsao K-C, Huang Y-C. A large-scale seroprevalence of Epstein–Barr virus in Taiwan. *PLoS ONE*. 2015. <https://doi.org/10.1371/journal.pone.0115836>.
26. Crawford DH, Swerdlow AJ, Higgins C, et al. Sexual history and Epstein–Barr virus infection. *J Infect Dis*. 2002;186:731–6.
27. Levine H, Balicer RD, Rozhavski V, et al. Seroepidemiology of Epstein–Barr virus and cytomegalovirus among Israeli male young adults. *Ann Epidemiol*. 2012;22:783–8.
28. Xu F-H, Xiong D, Xu Y-F, et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein–Barr virus activation. *J Natl Cancer Inst*. 2012;104:1396–410.
29. Goldacre MJ, Wotton CJ, Yeates DGR. Associations between infectious mononucleosis and cancer: record-linkage studies. *Epidemiol Infect*. 2009;137:672–80.
30. Hiscock R, Bauld L, Amos A, Platt S. Smoking and socioeconomic status in England: the rise of the never smoker and the disadvantaged smoker. *J Public Health*. 2012;34:390–6.
31. Romero-Masters JC, Huebner SM, Ohashi M, et al. B cells infected with Type 2 Epstein–Barr virus (EBV) have increased NFATc1/NFATc2 activity and enhanced lytic gene expression in comparison to Type 1 EBV infection. *PLoS Pathog*. 2020;16: e1008365.
32. Shi T, Balsells E, Wastnedge E, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. *J Glob Health*. 2015;5: 020416.

# Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

